- Home
- GLXG vs ATAI Comparison
GLXG vs ATAI Comparison
Compare GLXG & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLXG
- ATAI
- Stock Information
- Founded
- GLXG 2013
- ATAI 2018
- Country
- GLXG Hong Kong
- ATAI Germany
- Employees
- GLXG N/A
- ATAI N/A
- Industry
- GLXG
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- GLXG
- ATAI Health Care
- Exchange
- GLXG NYSE
- ATAI Nasdaq
- Market Cap
- GLXG 191.2M
- ATAI 214.8M
- IPO Year
- GLXG 2024
- ATAI 2021
- Fundamental
- Price
- GLXG $10.93
- ATAI $1.28
- Analyst Decision
- GLXG
- ATAI Strong Buy
- Analyst Count
- GLXG 0
- ATAI 3
- Target Price
- GLXG N/A
- ATAI $10.50
- AVG Volume (30 Days)
- GLXG 556.2K
- ATAI 658.5K
- Earning Date
- GLXG 11-16-2024
- ATAI 11-12-2024
- Dividend Yield
- GLXG N/A
- ATAI N/A
- EPS Growth
- GLXG N/A
- ATAI N/A
- EPS
- GLXG 0.06
- ATAI N/A
- Revenue
- GLXG $3,954,587.00
- ATAI $378,000.00
- Revenue This Year
- GLXG N/A
- ATAI $44.72
- Revenue Next Year
- GLXG N/A
- ATAI N/A
- P/E Ratio
- GLXG $177.36
- ATAI N/A
- Revenue Growth
- GLXG N/A
- ATAI 38.97
- 52 Week Low
- GLXG $3.83
- ATAI $1.03
- 52 Week High
- GLXG $13.89
- ATAI $2.85
- Technical
- Relative Strength Index (RSI)
- GLXG N/A
- ATAI 58.86
- Support Level
- GLXG N/A
- ATAI $1.18
- Resistance Level
- GLXG N/A
- ATAI $1.36
- Average True Range (ATR)
- GLXG 0.00
- ATAI 0.08
- MACD
- GLXG 0.00
- ATAI 0.02
- Stochastic Oscillator
- GLXG 0.00
- ATAI 75.76
About GLXG GALAXY PAYROLL GROUP LTD
Galaxy Payroll Group Ltd is a provider of payroll outsourcing services, employment services, consultancy and market research services based in Hong Kong. Its client base includes the retail and trading, industrial, IT, financial and professional services industries. The group generates majority of its revenues from clients in Hong Kong and PRC.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.